Inventory and Assessment: Healthcare System’s Oncology Data Assets

Comprehensive Inventory & Assessment of Integrated Health System’s Oncology Data

Matt Zuga, High Cape

“RNA is my go to firm for diligence, modeling and valuation projects. Responsive…check, reliable…check, understand my investments and companies…check.”

Market Assessment: Biopharma Company

Early-Stage Biopharma Company Needs Strategy and Research Support to Inform Prioritization

Kevin Slawin, Rapha Capital PE

“As the founder of Rapha Capital, an investment advisory, as well as the founder and/or board member of multiple private-stage companies in the biotech and medtech arenas, I’ve worked with RNA in many capacities, including target identification, diligence and in transaction advisory capacities. They are my “go to” firm to help me with all of […]

Buy-Side Due Diligence: Organ on a Chip

Buy-side Due Diligence Support for a Potential Investor

Fairness Opinion: General Partner-led Secondary Transaction

Royalty Fund Seeks to Make a Final Distribution to Limited Partners

Fairness Opinion: SPAC Target Company Valuation in Biotech

SPAC Seeks Target Company Valuation in Merger Consideration Transaction

Fairness Opinion: De-SPAC Transaction for Inflammatory Disorders Therapeutics Company

SPAC Seeks Independent Valuation of Target

Fairness Opinion: De-SPAC Transaction for T-Cell Therapeutics Company

SPAC Seeks Independent Valuation of Target Company in T-Cell Therapeutics

Fairness Opinion: De-SPAC Transaction for Private Biotech Company

SPAC Seeks Independent Valuation of Target in Mental Health Disorders